GenDx launches NGSgo-MX11-3 eleven loci multiplex for HLA typing by NGS

Utrecht, Netherlands – October 20, 2020. Genome Diagnostics B.V. ("GenDx") announced today the official launch of their new HLA typing product: NGSgo®-MX11-3.

NGSgo-MX11-3 is the latest addition to a series of previous developed singleplex (NGSgo-AmpX v2) and multiplex (NGSgo-MX6-1) amplification strategies for HLA typing by NGS. NGSgo-MX11-3 consists of amplification primers for eleven HLA genes (HLA-A, -B, -C, -DRB1, -DQB1 and -DPB1, DRB3/4/5, DQA1, and DPA-1) in three mixes per sample. The three-tube design results in low noise levels and well-balanced alleles, making the data quality of the 11-loci multiplex similar to a singleplex strategy.

Dr. Wietse Mulder, CEO of GenDx, commented: "If you want reliable genotyping with NGS, you need high data quality. GenDx investigated how to achieve the highest data quality with as few primer tubes as possible. The outcome was distributing the primers over three tubes. We noticed that this method yielded the best results. Next we spend much effort into setting up the protocol in such a way that it was easy to use, with high speed and few pipetting steps. I think the end result is something to be proud of."

NGSgo-MX11-3 has a whole-gene coverage approach, resulting in clear-cut genotyping with resolution of nearly all null alleles. The NGSgo workflow is very efficient with minimal cleanups and quantifications, so results can be obtained quickly. When amplification is started on day 1, the typing report is finished on day 2 before noon. Taken together, NGSgo-MX11-3 provides highly reliable HLA typing results in a very short time. NGSgo-MX11-3 is now available as RUO and GenDx is expecting that it will also become available as CE-marked IVD.

About HLA
The HLA system consists of a large family of highly variable genes and allelic variants which form the basis of the human immunological defense system. In stem cell transplantation, matching patient and donor is vital as small differences between HLA alleles may have serious effects on the outcome of transplantation. HLA typing is a technique that enables determination of specific nucleotide sequences, making it ideal for stem cell transplantation purposes. GenDx offers the NGSgo reagent line and the NGSengine software package for NGS-based HLA typing.

About GenDx
Genome Diagnostics B.V., also known as GenDx, is a Dutch company, founded in 2005, specialized in molecular diagnostics, focused on development, production and sales of innovative assays and analysis software for transplantation and companion diagnostics. GenDx also has a USA-based office near O'Hare airport, Chicago, IL.
GenDx specializes in HLA sequencing-based typing strategies and offers reagents and software for both Sanger and NGS approaches. Additionally, GenDx offers products for chimerism monitoring by qPCR and is developing products for chimerism monitoring by NGS. Thanks to its extensive in-house expertise, GenDx also offers custom laboratory services for basic and clinical research organizations.

GENDX

GenDx Education organizes dedicated HLA SBT and chimerism monitoring training courses worldwide on a regular basis for anyone working in tissue typing or research laboratories, blood banks, and donor registries.

GenDx is based at the Utrecht Science Park, the Netherlands and was founded in 2005 by Erik Rozemuller PhD, Wietse Mulder PhD and UMC Utrecht Holdings B.V. represented by Oscar Schoots PhD and Raoul Linschoten LLM. In 2019, Ampersand Capital Partners completed a minority growth equity investment in the company and David Parker joined the GenDx Board of directors along with Ampersand Operating Partner Mike Evans PhD. For further information about GenDx go to www.GenDx.com.

GenDx Netherlands
Yalelaan 48
3584 CM Utrecht
Office: +31 30 252 3799
E-mail: info@gendx.com

Contact GenDx
Wietse Mulder PhD
CEO
Email: w.mulder@gendx.com
Phone: +31 30 252 3799